PDCD1 and glioblastoma: To understand if immune subpopulations could be used as latent biomarkers of reaction to anti-PD-1 treatment, we analyzed two publicly available bulk RNA-seq datasets that included data of patients with glioblastomas who received anti-PD-1 treatment using pembrolizumab [38,39].